Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Summit links with Taiwan firm for lead product

This article was originally published in Scrip

Executive Summary

Summithas reached an agreement with the Taiwanese firm Orient Pharma to co-develop a buccal formulation of its lead product SMT D001. An oral formulation of the product, a combination of two marketed products with dry mouth as a side-effect, is in Phase II trials for sialorrhoea (excessive drooling) in Parkinson's disease patients. However, Summit has now suspended recruitment in this programme and will switch to the buccal formulation for future trials. Orient, a subsidiary ofOrient Europharma, will fund the development of the buccal formulation and also gains exclusive development and commercialisation rights in Asia and Australasia as part of the tie-up. It will cover all future costs related to the product in its territories, with Summit retaining rights in the rest of the world, where the UK firm is seeking partners.

You may also be interested in...

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Atlas, Rise! Japan Cancer Center Builds Asia Trial Network

Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts